Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Data from 20 patients with advanced solid tumors in the Phase I portion of an open-label, international Phase I/IIa trial showed that IV CRLX301 once every 3 weeks was generally well tolerated. The MT...